(Nature) – A single vaccine has been shown to protect people from both SARS-CoV-2 and influenza viruses — and with a higher effectiveness than vaccines that target one or the other, the pharmaceutical company Moderna has announced.

Moderna, which is based in Cambridge, Massachusetts, said earlier this month that it had successfully completed phase-III clinical trials for the drug, which — like the company’s pioneering COVID-19 vaccines — is based on mRNA. In a statement to its investors, Moderna said that the vaccine was more effective at providing immunity to adults over the age of 50 than competing flu and COVID-19 shots.

Moderna is now planning to seek approval from the US Food and Drug Administration (FDA) to bring the vaccine to market. (Read More)